Top 10 Korean Pharma Companies
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Address: 5F, DaeHan Bldg 201-6, Guui-Dong, Kwangjin-Gu Seoul,Republic of Korea
Tel: +82 2 456 3043
KRPIA represents Republic of Korean Research-based Pharmaceutical Industry Association. KRPIA is the association of research-based companies which deliver innovative new medicines to the market through incessant research endeavors. KRPIA was established in March 1999, consisting of 24 multinational research-based pharmaceutical companies operating in Republic of Korea. At present, KRPIA has 28 member companies which are taking the lead in the world’s pharmaceutical market. KRPIA believes ‘New Medicines, New Hope’ so it is devoted to providing new innovative drugs in Republic of Korea and disseminating pharmaceutical-related information. KRPIA members have the best possible conditions to research, develop, market and inform about their pharmaceuticals, thus ensuring broad and fast access for patients to the best medical treatment. The value of research based medicines for the Republic of Korean society is visible and recognized in a health system with the patient as priority. The Republic of Korean Research-based Pharmaceutical Industry Association is perceived as a responsible partner that makes a valuable contribution to society.Mision: Promote the development and prompt introduction of innovative new pharmaceuticals Enhance the ethical standards of the pharmaceutical industry Strengthen the pharmaceutical industry’s contribution to the advancement of public health Effectively disseminate pharmaceutical-related information and contribute to medical treatment for patients and public health promotion
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
See our Cookie Privacy Policy Here
